Meridian Biosciences (VIVO) PT Lowered to $14 at Baird Following Preliminary 2Q Miss
Tweet Send to a Friend
Baird analyst Catherine Schulte lowered the price target on Meridian Biosciences (NASDAQ: VIVO) to $14.00 (from $17.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
